Saturday, May 23, 2026
In Detail Full day, Saturday, May 23, 2026, Timezone: America/Chicago
Stem cells have potent potential for diabetes treatment
medicalxpress - Humans have around 30 trillion cells in our adult bodies. Amazingly, each of these cells came from a handful of about 100 stem cells in the earliest days of development. The ability of these embryonic stem cells to turn into any cell type makes them pluri…
AI Summary: Researchers report stem cell–based approaches can replenish insulin‑producing cells and restore glycemic control in diabetes models, offering a potential path beyond daily insulin injections. Early findings suggest significant therapeutic promise, but scientists stress that safety, durability, and immune‑rejection hurdles must be cleared before these techniques graduate from experimental hope to standard care.
An Ebola treatment tent is set ablaze again in eastern Congo with 18 suspected cases escaping
abcnews - A tent used for Ebola treatment in eastern Congo has been set on fire for the second time this week
AI Summary: In eastern Congo, an Ebola treatment tent was set ablaze, allowing at least 18 suspected patients to escape and disrupting outbreak containment efforts. The incident has drawn international scrutiny, with Congolese health officials publicly criticizing restrictive U.S. travel measures that complicate cross-border response and community trust.
Abridge names chief technology officer
Giles Bruce / beckershospitalreview - San Oo has been named chief technology officer of healthcare AI startup Abridge. Mr. Oo was most recently senior vice president of engineering at AI workspace developer Notion. He previously cofounded two tech companies that were acquired by LinkedIn and …
AI Summary: Abridge has appointed a new chief technology officer to lead its product and engineering strategy, signaling a push to scale its clinical AI tools and platform capabilities. The hire aims to strengthen technical leadership, accelerate development timelines, and reassure customers that the company intends to keep up with the fast-paced demands of healthcare AI — which, ironically, keeps hiring to stop churn.
- AI startups scale via health system partnerships (4)
- Practical challenges: accessibility, training, oversight of clinical AI (6)
- All Other Stories
AI startups scale via health system partnerships
Practical challenges: accessibility, training, oversight of clinical AI
All Other Stories
CommonSpirit $3.4B in the red amid billing contract exit, operational woes
Rebecca Pifer Parduhn / healthcaredive - The Catholic nonprofit giant’s expenses well outstripped revenue in the most recent financial quarter. Though the outcome was mostly due to one-time items, CommonSpirit also continues to struggle with boosting core operations.
AI Summary: CommonSpirit reported a multi‑billion‑dollar shortfall tied to operational challenges and the exit from a major billing contract, recording a substantial loss and a weakened operating margin in the quarter. The results have spurred leadership to reassess financial strategy and cost controls as the system navigates recovery and operational stabilization.
Nearly 10% of surgeons are leaving the profession within 8 years
medicalxpress - Surgeons are an integral part of the health care system, supplying critical and urgent care in nearly every field of medicine. But surgeons are already in short supply, with the gap between the number needed and the number working expected to get worse.
AI Summary: A recent report reveals that roughly one in ten surgeons leave clinical practice within eight years of starting, spotlighting a troubling attrition rate that threatens surgical capacity. The findings point to burnout, workload and systemic pressures as likely drivers and underscore the need for retention strategies, training support and policy changes to stabilize the surgical workforce.
FDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer approval
Lei Lei Wu / endpoints - The FDA has approved the TROP2-directed antibody-drug conjugate Datroway as a first-line option for triple-negative breast cancer, giving Daiichi Sankyo and AstraZeneca a leg up over their competitor Gilead. The approval marks Datroway’s third, after ...
AI Summary: Daiichi Sankyo and AstraZeneca’s breast cancer therapy Datroway has cleared key regulatory hurdles, winning FDA approval and earning backing from European regulators. The approvals validate pivotal trial results and pave the way for clinical adoption in the indicated patient population, prompting clinicians to prepare for integration into treatment pathways and health systems to weigh formulary and access decisions.
- Clinicians weigh Datroway’s role in TNBC care (3)
- FDA win and market stakes for Datroway (3)
- All Other Stories
Clinicians weigh Datroway’s role in TNBC care
FDA win and market stakes for Datroway
All Other Stories
Adding a Lower Cutoff Value for CA19-9 May Identify Additional High-risk Cases of Pancreatic Cancer
Kathleen Medora / aacr - CA19-9 is a biomarker whose levels often correlate with pancreatic cancer stage and prognosis PHILADELPHIA – A dual-threshold model for measuring the pancreatic tumor marker serum carbohydrate antigen 19-9 (CA19-9) identified patients with pancreatic canc…
AI Summary: Researchers propose lowering the CA19‑9 threshold to identify additional patients at high risk for pancreatic cancer. The analysis indicates the new cutoff improves detection of potentially dangerous cases without an unmanageable rise in false positives, offering a straightforward diagnostic tweak that could prompt earlier workups and treatment decisions.
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Trump Administration, Healthcare, Mergers and Acquisitions, Diabetes and look for the RSS link.
StackHealth Time Machine
More StackHealth